Beatrolol
Patent Foramen Ovale
Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05546320CT.gov Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Patent Foramen Ovale
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Beatrolol (this asset) | Chinese Academy of Medical Sciences, Fuwai Hospital | P2 | B · 56 |
| Aspirin | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Rivaroxaban | Chinese Academy of Medical Sciences, Fuwai Hospital | P3 | BB |
| Apixaban | Mayo Clinic | P3 | BB |
| Warfarin | Columbia University | P4 | BB |
| Dabigatran | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Flecainide | Assistance Publique - Hôpitaux de Paris | P3 | B |
| Prasugrel | Columbia University | P3 | B |
| Clopidogrel | Chinese Academy of Medical Sciences, Fuwai Hospital | P3 | NR |
Other indications for Beatrolol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Heart Disorder | — | P3 | B · 60 |
| Cardiomyopathy | — | P3 | B · 60 |
| Beta Thalassemia | — | P2/3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Beatrolol in Patent Foramen Ovale. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/beatrolol-patent-foramen-ovale
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →